EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Rationale and design of Low-Frequency REpetitive TRanscranial Magnetic Stimulation Combined with Endovascular Treatment in ACute Ischaemic StrokE (RETRACE II): a randomised double-blind controlled multicentre phase II pilot study

Lingling Ding, Wenjie Wang, Tingyu Yi, Gaocai Zhang, Xinsheng Han, Wenhuo Chen, Hao Wang, Yongjun Wang, Zixiao Li

Stroke and Vascular Neurology · 2026

DOI: 10.1136/svn-2025-004331 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stroke and Vascular Neurology, 2026. Verfasst von Lingling Ding und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Beijing Tiantan Hospital, Beijing, China. Hauptthemen laut MEDLINE: Endovascular Procedures, Ischemic Stroke, Transcranial Magnetic Stimulation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shenzhen Yingchi Technology Co.Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While endovascular therapy (EVT) remains the primary treatment for acute ischaemic stroke (AIS) management, persistent functional deficits in patients with successful recanalisation underscore the necessity for complementary neuroprotective strategies.

Aim

To investigate the safety and efficacy of low-frequency repetitive transcranial magnetic stimulation (LF-rTMS) as a potential adjunctive neuroprotective intervention following EVT in AIS patients.

Design

The Low-Frequency REpetitive TRanscranial Magnetic Stimulation Combined with Endovascular Treatment in ACute Ischaemic StrokE (RETRACE-II) trial is a phase II, multicentre, prospective, randomised, double-blind, sham-controlled pilot study. 60 successfully recanalised AIS patients with anterior circulation occlusion were equally randomised (1:1) to active LF-rTMS or sham intervention. The intervention involved administration of 1200-pulse 1-Hz LF-rTMS sessions (two times per day for 3 consecutive days) targeting the ipsilesional primary motor cortex (M1), initiated within 24 hours of symptom onset. Sham procedures maintained equivalent positioning with deactivated magnetic output. Standardised protocol assessments were conducted at 3-day (postintervention), 7-day and 90-day follow-ups. Study outcomes The primary efficacy endpoint was the proportion of early neurological recovery (defined as a reduction of ≥4 points on the National Institutes of Health Stroke Scale (NIHSS) or achieving a score of 0–1) at 3 days. Secondary outcomes included ischaemic penumbral salvage volume ratio, final infarct volume measured by brain MRI at 7 days, and modified Rankin Scale score at 90 days. Safety outcomes encompassed symptomatic intracranial haemorrhage, neurological deterioration (≥4-point increase in NIHSS score) and all-cause mortality through 90-day follow-up.

Discussion

RETRACE-II establishes methodological rigour for evaluating neuromodulation therapies during the hyperacute stroke phase, with findings expected to inform future trials and advance combination therapy paradigms in cerebrovascular neuroprotection. Trial registration number NCT06064747 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endovascular ProceduresIschemic StrokeTranscranial Magnetic StimulationAgedAged, 80 and overFemaleHumansMaleMiddle AgedCombined Modality TherapyDisability EvaluationDouble-Blind MethodFunctional StatusPilot ProjectsProspective StudiesRecovery of FunctionResearch DesignTime FactorsTreatment OutcomeMulticenter Studies as TopicRandomized Controlled Trials as TopicClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

Cerebral InfarctionStrokeTranscranial Magnetic Stimulation

Autor:innen und Institutionen

  • Department of Neurology, Beijing Tiantan Hospital, Beijing, China.
  • China National Clinical Research Center for Neurological Diseases, Beijing, China.
  • Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences, Beijing, China.
  • Department of Neurointervention, Zhangzhou Affiliated Hospital of Fujian Medical University, Fujian, China.
  • Department of Neurology, Kaifeng Central Hospital, Kaifeng, Henan, China.
  • Department of Cerebrovascular Disease, Fujian Medical University Union Hospital, Fujian, China.

Förderung

  • Shenzhen Yingchi Technology Co.Ltd

Zitieren

APA

Ding, L., Wang, W., Yi, T., Zhang, G., Han, X., Chen, W., Wang, H., Wang, Y., & Li, Z. (2026). Rationale and design of Low-Frequency REpetitive TRanscranial Magnetic Stimulation Combined with Endovascular Treatment in ACute Ischaemic StrokE (RETRACE II): a randomised double-blind controlled multicentre phase II pilot study. Stroke and Vascular Neurology. https://doi.org/10.1136/svn-2025-004331

Vancouver

Ding L, Wang W, Yi T, Zhang G, Han X, Chen W, et al. Rationale and design of Low-Frequency REpetitive TRanscranial Magnetic Stimulation Combined with Endovascular Treatment in ACute Ischaemic StrokE (RETRACE II): a randomised double-blind controlled multicentre phase II pilot study. Stroke and Vascular Neurology. 2026. doi:10.1136/svn-2025-004331

BibTeX
@article{Ding2026,
  author = {Ding, Lingling and Wang, Wenjie and Yi, Tingyu and Zhang, Gaocai and Han, Xinsheng and Chen, Wenhuo and Wang, Hao and Wang, Yongjun and Li, Zixiao},
  title = {Rationale and design of Low-Frequency REpetitive TRanscranial Magnetic Stimulation Combined with Endovascular Treatment in ACute Ischaemic StrokE (RETRACE II): a randomised double-blind controlled multicentre phase II pilot study},
  journal = {Stroke and Vascular Neurology},
  year = {2026},
  doi = {10.1136/svn-2025-004331}
}
Kostenlos starten →